FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Regulators | HIV | Generics | Merck | Adcock Ingram | Stocrin

SPOTLIGHT: Adcock Ingram gets free license for Merck HIV remedy

Tools

South African generics maker Adcock Ingram nabbed a royalty-free license from Merck on its anti-HIV drug Stocrin (efavirenz). The South African government has been buying the brand-name drug from Merck for distribution at state-run clinics. Adcock will sell its version at a "significant discount," once it gets approval from that country's drug regulators. Merck gave a voluntary license for efavirenz to Aspen Pharmacare, Adcock's biggest competitor, two years ago; that company still awaits regulatory approval for its version of the drug. Release


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:
Be the first to comment
More stories about Regulators   HIV   Generics   Merck   Adcock Ingram   Stocrin  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.